Do analysts recommend AVIR or MLTX?

MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 34.19%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 MoonLake Immunotherapeutics 3 Sell rating(s) 4 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has preferable earnings and valuation, AVIR or MLTX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is AVIR or MLTX more profitable?

Atea Pharmaceuticals' return on equity of -57.01% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Do analysts recommend AVIR or BCAX?

Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 48.36%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Bicara Therapeutics 1 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.73

Which has higher earnings and valuation, AVIR or BCAX?

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is AVIR or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -57.01% -51.49% Bicara Therapeutics N/A -35.89% -33.78%

Do analysts rate SEPN or AVIR?

Septerna currently has a consensus price target of $45.00, suggesting a potential upside of 42.93%. Given Septerna's stronger consensus rating and higher probable upside, equities analysts clearly believe Septerna is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Septerna 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts prefer URGN or AVIR?

Urogen Pharma presently has a consensus price target of $36.67, suggesting a potential upside of 32.92%. Given Urogen Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Urogen Pharma is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Urogen Pharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.80 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Do analysts recommend COAG or AVIR?

Hemab Therapeutics presently has a consensus price target of $41.75, suggesting a potential upside of 57.01%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Hemab Therapeutics is more favorable than Atea Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hemab Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, COAG or AVIR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hemab Therapeutics N/A N/A N/A N/A N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.11 N/A

Is COAG or AVIR more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Hemab Therapeutics N/A N/A N/A Atea Pharmaceuticals N/A -57.01% -51.49%

Atea Pharmaceuticals (AVIR) Competitors

$4.39 +0.07 (+1.62%)

As of 03:01 PM Eastern

Compare

AVIR vs. MLTX, BCAX, SEPN, URGN, and COAG

Should you buy Atea Pharmaceuticals stock or one of its competitors? MarketBeat compares Atea Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atea Pharmaceuticals include MoonLake Immunotherapeutics (MLTX), Bicara Therapeutics (BCAX), Septerna (SEPN), Urogen Pharma (URGN), and Hemab Therapeutics (COAG). These companies are all part of the "pharmaceutical products" industry.

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Atea Pharmaceuticals (NASDAQ:AVIR) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

MoonLake Immunotherapeutics has a consensus target price of $23.85, suggesting a potential upside of 34.19%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atea Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 5 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 5 mentions for MoonLake Immunotherapeutics and 0 mentions for Atea Pharmaceuticals. MoonLake Immunotherapeutics' average media sentiment score of 0.45 beat Atea Pharmaceuticals' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
MoonLake Immunotherapeutics	Neutral

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

Atea Pharmaceuticals' return on equity of -57.01% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Summary

Atea Pharmaceuticals beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Bicara Therapeutics?

Atea Pharmaceuticals (NASDAQ:AVIR) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

Bicara Therapeutics' return on equity of -35.89% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Bicara Therapeutics	N/A	-35.89%	-33.78%

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 48.36%. Given Bicara Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bicara Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Bicara Therapeutics had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for Bicara Therapeutics and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat Bicara Therapeutics' score of -0.18 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Neutral
Bicara Therapeutics	Neutral

Bicara Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Atea Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.54, suggesting that its share price is 154% less volatile than the broader market.

Summary

Bicara Therapeutics beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Septerna?

Septerna (NASDAQ:SEPN) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

In the previous week, Septerna had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Septerna and 0 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.00 beat Septerna's score of -0.03 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Septerna	Neutral
Atea Pharmaceuticals	Neutral

Septerna has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 4.3% of Septerna shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Atea Pharmaceuticals has a net margin of 0.00% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Septerna has higher revenue and earnings than Atea Pharmaceuticals. Septerna is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	30.89	-$48.88M	-$0.81	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Septerna currently has a consensus price target of $45.00, suggesting a potential upside of 42.93%. Given Septerna's stronger consensus rating and higher probable upside, equities analysts clearly believe Septerna is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Septerna beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Urogen Pharma?

Urogen Pharma (NASDAQ:URGN) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

Atea Pharmaceuticals has a net margin of 0.00% compared to Urogen Pharma's net margin of -94.83%. Urogen Pharma's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-94.83%	N/A	-62.85%
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Urogen Pharma has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Urogen Pharma has higher revenue and earnings than Atea Pharmaceuticals. Urogen Pharma is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	12.24	-$153.49M	-$2.75	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Urogen Pharma presently has a consensus price target of $36.67, suggesting a potential upside of 32.92%. Given Urogen Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Urogen Pharma is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Urogen Pharma had 4 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Urogen Pharma and 0 mentions for Atea Pharmaceuticals. Urogen Pharma's average media sentiment score of 0.16 beat Atea Pharmaceuticals' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Urogen Pharma	Neutral
Atea Pharmaceuticals	Neutral

Summary

Urogen Pharma beats Atea Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Hemab Therapeutics presently has a consensus price target of $41.75, suggesting a potential upside of 57.01%. Given Hemab Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Hemab Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Hemab Therapeutics had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 3 mentions for Hemab Therapeutics and 0 mentions for Atea Pharmaceuticals. Hemab Therapeutics' average media sentiment score of 0.00 equaled Atea Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Hemab Therapeutics	Neutral
Atea Pharmaceuticals	Neutral

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Hemab Therapeutics' return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	-57.01%	-51.49%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A

Summary

Hemab Therapeutics beats Atea Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$352.53M	$3.32B	$6.49B	$11.92B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	-2.09	19.11	23.98	23.72
Price / Sales	N/A	305.35	531.00	116.36
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.24	8.17	10.57	6.75
Net Income	-$158.35M	$23.83M	$3.56B	$337.25M
7 Day Performance	2.81%	-2.68%	-0.84%	-2.31%
1 Month Performance	-19.15%	2.38%	1.41%	1.62%
1 Year Performance	36.76%	37.71%	21.44%	24.64%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	0.5244 of 5 stars	$4.39 +1.6%	N/A	+35.8%	$352.53M	N/A	N/A	70	Positive News
MLTX MoonLake Immunotherapeutics	3.6765 of 5 stars	$17.87 -5.0%	$23.85 +33.4%	-61.6%	$1.39B	N/A	N/A	2	Positive News Analyst Forecast
BCAX Bicara Therapeutics	1.9452 of 5 stars	$19.64 -4.8%	$30.27 +54.1%	+74.8%	$1.35B	N/A	N/A	32
SEPN Septerna	2.3642 of 5 stars	$29.94 -0.1%	$43.13 +44.0%	+197.8%	$1.35B	$45.95M	N/A	N/A	News Coverage Analyst Forecast High Trading Volume
URGN Urogen Pharma	3.3789 of 5 stars	$26.54 -1.8%	$36.67 +38.2%	+269.7%	$1.32B	$109.79M	N/A	200	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MLTX, BCAX, SEPN, URGN, and COAG

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Summary

How does Atea Pharmaceuticals compare to Bicara Therapeutics?

Summary

How does Atea Pharmaceuticals compare to Septerna?

Summary

How does Atea Pharmaceuticals compare to Urogen Pharma?

Summary

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. MLTX, BCAX, SEPN, URGN, and COAG

How does Atea Pharmaceuticals compare to MoonLake Immunotherapeutics?

Do analysts recommend AVIR or MLTX?

Do insiders & institutionals have more ownership in AVIR or MLTX?

Which has more risk & volatility, AVIR or MLTX?

Does the media refer more to AVIR or MLTX?

Which has preferable earnings and valuation, AVIR or MLTX?

Is AVIR or MLTX more profitable?

Summary

How does Atea Pharmaceuticals compare to Bicara Therapeutics?

Is AVIR or BCAX more profitable?

Do insiders and institutionals have more ownership in AVIR or BCAX?

Do analysts recommend AVIR or BCAX?

Does the media prefer AVIR or BCAX?

Which has higher earnings and valuation, AVIR or BCAX?

Which has more risk and volatility, AVIR or BCAX?

Summary

How does Atea Pharmaceuticals compare to Septerna?

Does the media favor SEPN or AVIR?

Which has more volatility & risk, SEPN or AVIR?

Do institutionals & insiders believe in SEPN or AVIR?

Is SEPN or AVIR more profitable?

Which has higher earnings and valuation, SEPN or AVIR?

Do analysts rate SEPN or AVIR?

Summary

How does Atea Pharmaceuticals compare to Urogen Pharma?

Is URGN or AVIR more profitable?

Which has more risk and volatility, URGN or AVIR?

Do insiders and institutionals hold more shares of URGN or AVIR?

Which has preferable earnings and valuation, URGN or AVIR?

Do analysts prefer URGN or AVIR?

Does the media favor URGN or AVIR?

Summary

How does Atea Pharmaceuticals compare to Hemab Therapeutics?

Do analysts recommend COAG or AVIR?

Does the media refer more to COAG or AVIR?

Do institutionals and insiders hold more shares of COAG or AVIR?

Is COAG or AVIR more profitable?

Which has preferable earnings & valuation, COAG or AVIR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools